210 / 320
614
12. Carlier M, Stove V, Wallis SC, De Waele JJ, Verstraete AG, Lipman
J, et al. Assays for therapeutic drug monitoring of beta-lactam
antibiotics: A structured review. Int J Antimicrob Agents.
2015;46(4):367–75.
13. Dulhunty JM, Roberts J a, Davis JS, Webb S a R, Bellomo R,
Gomersall C, et al. Continuous infusion of beta-lactam antibiotics
in severe sepsis: a multicenter double-blind, randomized
controlled trial. Clin Infect Dis. 2013;56(2):236–44.
14. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts J a. Does Beta-
lactam Pharmacokinetic Variability in Critically Ill Patients Justify
Therapeutic Drug Monitoring? A Systematic Review. Annals of
Intensive Care; 2012;2(1):35.
15. Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R,
Hope WW. Therapeutic drug monitoring (TDM) of antifungal
agents: Guidelines from the british society for medical mycology.
J Antimicrob Chemother. 2014;69(5):1162–76.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM,
et al. Surviving sepsis campaign: international guidelines for
management of severe sepsis and septic shock: 2012. Crit Care
Med. 2013;39(2):165–228.
17. Tomlin M. Pharmacology & Pharmacokinetics. A basic reader.
London: Springer; 2009. 1-170 p.
18. Bonate P. Pharmacokinetic - Pharmacodynamic Modeling and
Simulation. Second Edition. London: Springer; 2011. 618 p.
19. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS,
Kauffman RE. Developmental pharmacology--drug disposition,
action, and therapy in infants and children. N Engl J Med.
2003;349(12):1157–67.
20. Aymanns C, Keller F, Maus S, Hartmann B, Czock D. Review on
pharmacokinetics and pharmacodynamics and the aging kidney.
Clin J Am Soc Nephrol. 2010;5(2):314–27.
21. Rodieux F, Wilbaux M, van den Anker JN, Pfister M. Effect of kidney
function on drug kinetics and dosing in neonates, infants, and
children. Clin Pharmacokinet. 2015;54(12):1183–204.
22. Escobar L, Gai MN, Regueira T, Andresen M. Consideraciones
farmacocinéticas en el paciente crítico. Rev Med Chil.
2012;780–8.
23. Varghese JM, Roberts JA, Lipman J. Pharmacokinetics and
pharmacodynamics in critically ill patients. Curr Opin
Anaesthesiol. 2010;23:472–8.
24. Cheymol G. Effects of obesity on pharmacokinetics implications
for drug therapy. Clin Pharmacokinet. 2000;39(3):215–31.
25. Stepensky D. Prediction of drug disposition on the basis of its
chemical structure. Clin Pharmacokinet. 2013;52(6):415–31.
26. Greenberg E, Saad N. Drug dosage adjustment using renal
estimation equations: A review of the literature. Hosp Pharm.
2009;44(7):577–84.
27. FDA. Guidance for Industry Bioanalytical Method Validation.
2001.
28. Peters FT, Drummer OH, Musshoff F. Validation of new methods.
Forensic Sci Int. 2007;165(2-3):216–24.
29. EMA. Guideline on bioanalytical method validation [Internet].
Committee for Medicinal Products for Human Use (CHMP). 2011.
Available from:
www.ema.europa.eu30. Adaway JE, Keevil BG. Therapeutic drug monitoring and LC-MS/
MS. J Chromatogr B. 2012;883-884:33–49.
31. Pauwels S, Allegaert K. Therapeutic drug monitoring in neonates.
Arch Dis Child. 2016;1:377–81.
32. Patsalos PN, Berry DJ. Therapeutic drugmonitoring of antiepileptic
drugs by use of saliva. Ther Drug Monit. 2013;35(1):4–29.
[REV. MED. CLIN. CONDES - 2016; 27(5) 605-614]